The Toro Company reported strong Q3 2026 results, exceeding revenue and EPS expectations, and raised its full-year sales and EPS guidance due to strong demand and margin expansion. However, shares dropped nearly 7% amid concerns about the quality of earnings, particularly margin contraction and ongoing input cost pressures in the professional segment. Despite appearing undervalued based on free cash flow, the analyst maintains a Hold rating due to doubts over earnings reliability. The company’s growth was supported by acquisitions and robust residential margins, but risks remain from cost pressures.
Oracle reported strong fiscal 2026 results with 17% revenue growth to $67 billion and a 36% net income increase, driven by a 75% surge in its cloud infrastructure segment. Despite a recent 55% stock price drop from its peak, Morgan Stanley raised Ora...
RBC Capital increased its price target for cybersecurity firm Zscaler to $210, maintaining an "Outperform" rating due to the company's strong financial results and AI innovation. Zscaler reported a 25% rise in revenue and Annual Recurring Revenue, su...
Lululemon Athletica's shares fell about 18% after the company lowered its full-year financial forecast for the second time, reflecting ongoing challenges. In Q2 2026, total net revenue dropped 4% to $2.40 billion, with a 10% fall in comparable sales ...
Teva Pharmaceutical Industries received a boost as UBS reaffirmed its "Buy" rating and raised the price target to $48, up from $36.62. This follows positive Phase 2a clinical trial results for TEV '408, a drug showing significant prevention of intest...
UiPath reported strong fiscal Q2 results with $410.26 million revenue and 12% ARR growth, beating estimates. However, analyst caution arises from its high valuation, modest growth compared to AI-focused peers, and recent insider selling by CEO and ex...
